Table 3.

Univariate analyses of CCL5, ER-α, ER-β, PR, and ErbB2 expression in breast cancer patients using Cox proportional hazard models

	P	HR	95% limits
Stage I
CCL5	0.9086	1.046	0.489, 2.237
ER-α	0.6311	0.831	0.389, 1.772
ER-β	0.6745	0.814	0.312, 2.126
PR	0.5044	0.772	0.362, 1.648
ErbB2	0.0563	2.123	0.980, 4.599
CCL5⁺/ErbB2⁺	0.3856	1.496	0.602, 3.715
Stage II
CCL5	0.0045	2.218	1.280, 3.844
ER-α	0.0041	0.458	0.269, 0.780
ER-β	0.9156	0.971	0.568, 1.661
PR	0.0107	0.499	0.292, 0.851
ErbB2	0.2307	1.441	0.793, 2.618
CCL5⁺/ER-α⁻	0.0001	3.455	1.838, 6.491
CCL5⁺/PR⁻	0.0253	2.016	1.091, 3.727
CCL5⁺/ErbB2⁺	0.0140	2.310	1.184, 4.506
CCL5⁻/ER-α⁺	0.0029	0.387	0.207, 0.722
CCL5⁻/PR⁺	0.0005	0.277	0.135, 0.569
Stage IIA
CCL5	0.0610	1.982	0.969, 4.055
ER-α	0.0315	0.470	0.236, 0.935
PR	0.0260	0.458	0.230, 0.910
CCL5⁺/ER-α⁻	0.0003	5.680	2.203, 14.64
CCL5⁺/PR⁻	0.0523	2.425	0.991, 5.932
CCL5⁻/ER-α⁺	0.0488	0.481	0.233, 0.996
CCL5⁻/PR⁺	0.0092	0.345	0.155, 0.769
Stage IIB
CCL5	0.1758	2.013	0.731, 5.543
ER-α	0.1739	0.546	0.228, 1.306
PR	0.4496	0.715	0.299, 1.708
CCL5⁺/ER-α⁻	0.1715	1.870	0.762, 4.587
CCL5⁺/PR⁻	0.5642	1.299	0.534, 3.162
CCL5⁻/ER-α⁺	0.1109	0.304	0.070, 1.314
CCL5⁻/PR⁺	0.0917	0.177	0.024, 1.325

NOTE: The analysis includes 53 patients at stage I of disease and 89 patients at stage II of disease. Stage II patients were further divided to stage IIA (62 patients) and stage IIB (27 patients).
Abbreviation: HR, hazard ratio.